| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Cytosine is an aminopyrimidine that is pyrimidin-2-one having the amino group located at position 4. It has a role as a human metabolite, an Escherichia coli metabolite, a Saccharomyces cerevisiae metabolite and a mouse metabolite. It is a pyrimidine nucleobase, a pyrimidone and an aminopyrimidine.
Cytosine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Cytosine has been reported in Camellia sinensis, Glycine max, and other organisms with data available. Cytosine is a pyrimidine base found in DNA and RNA that pairs with guanine. Cytosine is a metabolite found in or produced by Saccharomyces cerevisiae. A pyrimidine base that is a fundamental unit of nucleic acids. See also: Pyrimidine (subclass of). |
| Molecular Formula |
C4H5N3O
|
|---|---|
| Molecular Weight |
111.1
|
| Exact Mass |
111.043
|
| CAS # |
71-30-7
|
| Related CAS # |
52685-04-8;26297-64-3
|
| PubChem CID |
597
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
445.8ºC at 760 mmHg
|
| Melting Point |
>300 °C(lit.)
|
| Flash Point |
223.4ºC
|
| Index of Refraction |
1.689
|
| LogP |
-2.29
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
170
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N=C([H])C([H])=C(N([H])[H])N1[H]
|
| InChi Key |
OPTASPLRGRRNAP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H5N3O/c5-3-1-2-6-4(8)7-3/h1-2H,(H3,5,6,7,8)
|
| Chemical Name |
6-amino-1H-pyrimidin-2-one
|
| Synonyms |
NSC27787; NSC-27787; NSC 27787
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~150.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (15.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (15.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.0009 mL | 45.0045 mL | 90.0090 mL | |
| 5 mM | 1.8002 mL | 9.0009 mL | 18.0018 mL | |
| 10 mM | 0.9001 mL | 4.5005 mL | 9.0009 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05578378 | Recruiting | Drug: CladribineDrug: Fludarabine |
Acute Lymphoblastic Leukemia |
The First Affiliated Hospital of Soochow University |
January 1, 2022 | Phase 2 Phase 3 |
| NCT05773196 | Recruiting | Other:Biospecimen Collection | Huntington Disease Huntington's Dementia |
Sanguine Biosciences | March 14, 2023 | |
| NCT04406636 | Active, not recruiting | Huntington Disease | CHDI Foundation, Inc. | May 19, 2020 | ||
| NCT04168502 | Recruiting | Drug: Glasdegib Drug: Gemtuzumab Ozogamicin |
Acute Myeloid Leukemia | Gruppo Italiano Malattie EMatologiche dell'Adulto |
September 24, 2020 | Phase 3 |
| NCT05624827 | Recruiting | Diagnostic Test: Testing DNA | Cervical Intraepithelial Neoplasia Grade 2 |
University Medical Centre Maribor |
September 1, 2021 | Not Applicable |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
